AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
MWN-AI** Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced a significant development with the acceptance of a late-breaking abstract for presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting, taking place from November 5-9, 2025, in National Harbor, Maryland. The research, conducted by the University of Pittsburgh Medical Center (UPMC), centers around a Phase 2 clinical study investigating the efficacy of Ampligen® (rintatolimod) in patients with advanced recurrent ovarian cancer who have developed resistance to cisplatin.
The abstract, titled "A Phase II Trial of Combination Locoregional Chemoimmunotherapy in Recurrent Platinum-Sensitive Ovarian Cancer Triggers a T Lymphotactic Response Correlating with Clinical Outcomes," will be presented by Dr. Mackenzy M. Radolec, a Clinical Assistant Professor at the UPMC Magee-Women's Hospital. The session is slated for November 7, 2025, in the Prince George ABC Exhibit Halls at the Gaylord National Resort and Convention Center.
AIM ImmunoTech is dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen® at the forefront of its research portfolio. This drug is a first-in-class, investigational agent known for its selective TLR3 agonist properties and broad-spectrum activity across significant clinical trials.
As AIM moves forward, it emphasizes the need for investors to approach the results with caution due to the inherent risks and uncertainties tied to clinical success and regulatory approval processes. The company has advised stakeholders to review their most recent SEC filings for potential risk factors. AIM continues to engage with the investment community through various platforms, providing updates on its research and future plans.
MWN-AI** Analysis
AIM ImmunoTech Inc. (NYSE American: AIM) has made headlines with the announcement that their late-breaking abstract from the University of Pittsburgh Medical Center will be presented at the prestigious 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting. This moment highlights a critical juncture for AIM, particularly regarding the clinical data from their Phase 2 study focusing on cisplatin-resistant advanced recurrent ovarian cancer utilizing Ampligen® (rintatolimod).
Investors should approach AIM's stock with cautious optimism. The presentation, scheduled for November 7, 2025, may serve to elevate AIM’s visibility within the oncology community and potentially lead to increased interest from institutional investors, which is vital given the competitive landscape of immunotherapies. The study's focus on a pressing medical need, such as cisplatin-resistant ovarian cancer, underscores the importance of AIM's research efforts.
However, potential investors should remain vigilant about the inherent risks. Clinical trials, while promising, do not guarantee approval for new therapies. The verbiage in AIM’s cautionary statement emphasizes that results from clinical studies won't necessarily translate to future market success. Investors should heed the company's previous risk disclosures, particularly those included in their Form 10-K filings.
Overall, while AIM’s announcement could provide a short-term boost due to heightened interest around the SITC meeting, the market reaction will depend on the specifics of the data presented and broader investor sentiment. Keeping an eye on post-presentation market reactions and any subsequent analyst updates will be key for investors considering taking a position in AIM ImmunoTech.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen ® (rintatolimod) was accepted in a late-breaking abstract at the 40 th Annual SITC Meeting being held November 5-9, 2025 at National Harbor, MD.
Details of the poster presentation are as follows:
Title: A Phase II Trial of Combination Locoregional Chemoimmunotherapy in Recurrent Platinum-Sensitive Ovarian Cancer Triggers a T Lymphotactic Response Correlating with Clinical Outcomes
Presenting Author: Mackenzy M. Radolec, MD, Clinical Assistant Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, UPMC Magee-Women’s Hospital
Abstract Number: 1343
Date: Friday, November 7, 2025
Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center
For more information about the SITC Annual Meeting, please visit sitcancer.org .
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
Cautionary Statement:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
FAQ**
How has the clinical data from the Phase 2 cisplatin-resistant advanced recurrent ovarian cancer study impacted the market perception of AIM ImmunoTech Inc. AIM and its lead product, Ampligen® (rintatolimod)?
What specific clinical outcomes correlating with the T Lymphotactic response were highlighted in the late-breaking abstract by AIM ImmunoTech Inc. AIM at the SITC Meeting, and how might these outcomes influence future trials?
Given the ongoing development of Ampligen®, how does AIM ImmunoTech Inc. AIM plan to address the various risks and uncertainties mentioned in their forward-looking statements, particularly concerning regulatory approval?
In what ways could the presentation at the SITC Meeting enhance AIM ImmunoTech Inc. AIM's visibility and credibility within the oncology community and potential investors?
**MWN-AI FAQ is based on asking OpenAI questions about AIM ImmunoTech Inc. (NYSE: AIM).
NASDAQ: AIM
AIM Trading
57.55% G/L:
$0.4038 Last:
448,184,778 Volume:
$0.2756 Open:
